Xiaonan Yan

Dr. Xiaonan Yan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
ZGZixuan Gao
Zixuan Gao
GWGui Wang
Gui Wang
XMXiaochen Ma
Xiaochen Ma
HTHuihui Tan
Huihui Tan
CZChu Zhang
Chu Zhang
XYXiaonan Yan
Xiaonan Yan
Polycystic ovary syndrome (PCOS) is an extremely common endocrine-metabolic disorder and the main cause of infertility in premenopausal women, thus targeted treatments are sorely needed. Accumulative evidence showed that exogenous supplementation of IL-22 in PCOS mice may be of significant positive effect on insulin resistance (IR), a root causative factor for this condition, but much remained unknown about its mechanism. According to our previous study, troxerutin, a common anticoagulant and thrombolytic agent in clinic, alleviated various PCOS-like phenotypes in dihydrotestosterone (DHT)-treated rat model with unclear mechanism. Here, glucose tolerance tests (GTTs), insulin tolerance tests (ITTs), and homeostatic model assessment of insulin resistance (HOMA-IR) analyses revealed that troxerutin treatment in DHT-treated rats also significantly improved insulin resistance and enhanced serum IL-22 levels, which thereby activated IL-22R1/Janus kinase 1 (JAK1)/signal transducer and activator of transcription-3 (STAT3) signaling pathway in pancreatic islet. This protective effect of troxerutin on insulin resistance improvement was blocked by an inhibitor of p-STAT3, S3I-201. Troxerutin administration to DHT rats decreased the relative abundance of Bifidobacterium and enhanced secondary bile acid profiles, which were positively correlated with serum IL-22 concentration. Conclusively, the present study reported that troxerutin is an endogenous enhancer of IL-22 and the effect of troxerutin on insulin resistance improvement was via IL-22R1/JAK1/STAT3 signaling activation in a DHT-induced PCOS rat model. These insights may be translated into a primary therapeutic agent for PCOS with insulin resistance and hyperandrogenism. NEW & NOTEWORTHY Troxerutin decreased the relative abundance of Bifidobacterium, along with enhancement of secondary bile acids/IL-22 system, which thereby activated its downstream IL-22R1/JAK1/STAT3 signaling pathway in pancreatic β cells, subsequently attenuated insulin resistance (IR), hyperandrogenism and PCOS-like phenotypes in DHT-induced PCOS rat models. Troxerutin is an endogenous IL-22 enhancer and may be of therapeutic value for PCOS with insulin resistance.

13 September 2020 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
ZGZixuan Gao
Zixuan Gao
XMXiaochen Ma
Xiaochen Ma
JLJing Liu
Jing Liu
YGYuhang Ge
Yuhang Ge
LWLei Wang
Lei Wang
XYXiaonan Yan
Xiaonan Yan
The exact pathogenesis of polycystic ovary syndrome (PCOS), the most common neuroendocrine disorder in women of reproductive age, has not been fully elucidated. Recent studies suggested that chronic inflammation and neurotransmitter disorder involved in the progress of PCOS. Troxerutin, a natural flavonoid, was reported to possess neuroprotective effect in several disease models by inhibiting inflammation or enhancing neurotrophic factor. In this study, we investigated the possible protective effect and mechanism of troxerutin in a dihydrotestosterone (DHT)-induced rat model of PCOS. The PCOS rat models were treated with troxerutin at a dose of 150 mg/kg or 300 mg/kg for up to 4 weeks. Results showed that 300 mg/kg troxerutin significantly decreased the body weight gain and improved the pathological changes of ovary induced by DHT. Meanwhile, the elevated gonadotrophin-releasing hormone (GnRH), gonadotrophin and testosterone in the serum of PCOS rats were reduced with the treatment of troxerutin. The expression of kisspeptin and NKB in arcuate nucleus and their receptors kiss1r and NK3r in GnRH positive neurons of median eminence were markedly decreased in troxerutin-treated rats. Of note, the GnRH inhibitory regulator GABA and stimulatory regulator glutamate were also restored to the normal level by troxerutin. The present study indicated that troxerutin may exhibit a protective effect in PCOS rat model via regulating neurotransmitter release.

17 August 2021 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
QYQianqian Yin
Qianqian Yin
JZJianhua Zheng
Jianhua Zheng
YCYijuan Cao
Yijuan Cao
XYXiaonan Yan
Xiaonan Yan
HZHong Zhang
Hong Zhang
Objectives. According to the International Diabetes Federation (IDF) criteria, previous studies in Chinese women with polycystic ovary syndrome (PCOS) reported a low prevalence of metabolic syndrome (MS); however, the same population predisposed to developing pre-MS. Early identification and treatment of individuals with MS and pre-MS are imperative to prevent their adverse consequences. Moreover, fasting plasma glucose (FPG) was not accurate in detecting pathoglycemia in women with PCOS as they have shown characteristically postprandial abnormalities in the carbohydrate metabolism. Therefore, we aimed to compare the discriminative performance of various indices for identifying MS and pre-MS/MS (pre-MS and MS) using the updated Chinese Diabetes Society (uCDS) criteria in Chinese women with PCOS. Methods. 1083 Chinese women with PCOS were included in this study. We measured and evaluated 8 indices in all individuals. Based on the uCDS criteria for MS, patients who had no less than two components of MS but did not meet the criteria for the diagnosis of MS were considered as having pre-MS. Receiver operating characteristic (ROC) curves and the area under ROC curves (AUCs) levels were used to assess the accuracy of each index in detecting MS and pre-MS/MS. Results. Among the 8 indices assessed, the lipid accumulation product (LAP) provided the highest AUCs for detecting MS and pre-MS/MS, followed by CVAI, WTI, VAI, TyG, TG/HDL, WC, and BMI. The optimal cutoff points determined for LAP were 45.13 (sensitivity 88.0, specificity 88.4, and Youden index 0.764) for MS and 28.01 (sensitivity 87.5, specificity 80.7, and Youden index 0.681) for pre-MS/MS, respectively. Conclusions. uCDS criteria are reasonably more suitable for detecting MS and pre-MS in Chinese women with PCOS. Based on this criterion, LAP is the best index for the diagnosis of MS and pre-MS/MS in Chinese women with PCOS, out of the 8 obesity and lipid-related indices assessed.

17 December 2023 in Phytomedicine
Verified
Journal Article
Closed access
ZGZixuan Gao
Zixuan Gao
HTHuihui Tan
Huihui Tan
XSXueli Song
Xueli Song
TZTao Zhuang
Tao Zhuang
RKRenyu Kong
Renyu Kong
RYRuiqin Yao
Ruiqin Yao

18 February 2021 in Gynecologic and Obstetric Investigation
Verified
Journal Article
Closed access
PDF file
YQYujuan Qi
Yujuan Qi
QYQianqian Yin
Qianqian Yin
JGJuan Gu
Juan Gu
YLYing Liu
Ying Liu
QSQingqing Sun
Qingqing Sun
JWJie Wu
Jie Wu
Objectives: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disease. Some studies reported that the development of PCOS may be closely related to insulin resistance (IR). Interestingly, the long noncoding RNA (lncRNA) ENST00000550337.1 in peripheral blood is mainly involved in glucose metabolism. Therefore, the purpose of our study was to explore the relationship between lncRNA ENST00000550337.1 level and PCOS patients. Materials and Methods: Seventy-five PCOS patients and 72 healthy controls were enrolled in this study. We used qRT-PCR to detect the expression level of lncRNA ENST00000550337.1 in peripheral blood leukocytes from patients with PCOS. We also investigated potential relationships between lncRNA ENST00000550337.1 and the endocrine parameters in PCOS. Results: We observed that the expression of lncRNA ENST00000550337.1 in PCOS patients was significantly higher than that in the control subjects and positively correlated with PCOS occurrence, waist circumference, waist-hip ratio, IR, fasting insulin levels, and blood glucose. The expression of lnc RNA ENST00000550337.1 was positively correlated with PCOS (p = 0.003). There were independent correlations between IR and expression of lncRNA ENST00000550337.1 in patients with PCOS. Patients with elevated lncRNA ENST00000550337.1 expression had significantly increased PCOS risk after adjusting for age and BMI. LncRNA ENST00000550337.1 expression level provided a sensitivity of 81.3% and a specificity of 78.1% with a threshold value of 6.4648 for the prediction of PCOS. The area under the ROC was 0.813. Limitations: There are some limitations to this study. First, the sample size was limited and the causal relationship between lncRNA ENST00000550337.1 and PCOS was not investigated due to the cross-sectional study design. Second, HOMA-IR does not fully accurately reflect the IR of patients. Conclusions: The present study indicated that lnc RNA ENST00000550337.1 was related to PCOS occurrence, and elevated levels may be a risk factor for PCOS women. In addition, lncRNA ENST00000550337.1 might promote PCOS development partially by increasing IR and can be used as a potential molecular marker in patients with PCOS.

15 May 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
QYQianqian Yin
Qianqian Yin
JZJianhua Zheng
Jianhua Zheng
YCYijuan Cao
Yijuan Cao
XYXiaonan Yan
Xiaonan Yan
HZHong Zhang
Hong Zhang
Objective: Proteomic analysis was conducted on human follicular fluid (FF) using the 4D label-free method to identify proteins potentially influencing oocyte quality in hyperandrogenic (HA) polycystic ovary syndrome (PCOS) patients.Methods: FF was collected from 3 different groups: HA PCOS patients, non-hyperandrogenic (NHA) PCOS patients, and controls. Protein profiles of FF from HA PCOS patients (n = 10) were constructed utilizing 4D label-free proteomics technology. Differentially expressed proteins were identified by comparing these profiles with those from NHA PCOS (n = 10) and control patients (n = 10). In addition, FF was collected from 34 HA, 33 NHA, and 23 control patients for enzyme-linked immunosorbent assay (ELISA) validation of differentially expressed proteins. Associations between the levels of differentially expressed proteins in FF and various embryonic outcome indicators were evaluated.Results: The HA group demonstrated significantly reduced normal cleavage rates, D3 available embryo rates, D3 high-quality embryo rates, available blastocyst rates, and high-quality blastocyst rates compared to the NHA and control groups (HA vs. NHA vs. Control, 88.3 vs. 93.6 vs. 94.23, 70.57 vs. 81.76 vs. 83.77, 42.49 vs. 56.39 vs. 61.83, 55.0 vs. 65.96 vs. 67.26, 27.62 vs. 45.19 vs. 44.75, respectively), with statistically significant differences (P < 0.05). 23 differentially expressed proteins were identified in FF profiles of the HA group relative to the control group, while 9 differentially expressed proteins were noted in comparison with the NHA group. Cross-comparison highlighted three potential target proteins: insulin-like growth factor binding protein 5 (IGFBP5), lysosomal-associated membrane protein 2 (LAMP2), and cadherin-5 (CDH5). Adjusting for age and body mass index (BMI), IGFBP5 levels in FF exhibited negative correlations with normal cleavage rate, D3 high-quality embryo rate, available blastocyst rate, and high-quality blastocyst rate (P ≤ 0.05). Similarly, LAMP2 levels were negatively correlated with normal cleavage rate, D3 available embryo rate, D3 high-quality embryo rate, and high-quality blastocyst rate (P < 0.05). CDH5 levels demonstrated positive correlations with D3 high-quality embryo rate and high-quality blastocyst rate (P < 0.05).Conclusion: The proteins IGFBP5, LAMP2, and CDH5 may contribute to the mechanisms underlying the adverse effects of hyperandrogenism on oocyte quality in PCOS patients.